Beltz Justin, Pfaff Annalise, Abdullahi Ibrahim Munkaila, Cristea Alex, Mochalin Vadym N, Ercal Nuran
Department of Chemistry, Missouri University of Science & Technology, 400 W. 11 Street, 104 Schrenk Hall, Rolla, MO 65409, USA.
Department of Materials Science & Engineering, Missouri University of Science & Technology, MO 65409, USA.
Diam Relat Mater. 2019 Dec;100. doi: 10.1016/j.diamond.2019.107590. Epub 2019 Oct 22.
Tiopronin is an FDA-approved thiol drug currently used to treat cystinuria and rheumatoid arthritis. However, due to its antioxidant properties, it may be beneficial in a variety of other conditions. One primary obstacle to its wider application is its limited bioavailability, which necessitates administration of high systemic doses to achieve localized therapeutic effects. Incorporation of a drug delivery vehicle can solve this dilemma by providing a means of controlled, targeted release. Functionalized nanodiamond is a promising theranostic platform that has demonstrated great potential for biomedical applications, including drug delivery. Design of nanodiamond theranostic platforms requires comprehensive understanding of drug-platform interactions, and the necessary physical chemical investigations have only been realized for a limited number of compounds. Towards the long-term goal of developing a nanodiamond-tiopronin treatment paradigm, this study aims to shed light on the effects of nanodiamond surface chemistry on adsorption and release of tiopronin. Specifically, adsorption isotherms were measured and fit to Langmuir and Freundlich models for carboxylated, hydroxylated, and aminated nanodiamonds, and release was monitored in solutions at pH 4.0, 5.8, 7.3, and 8.1. Our results indicate that aminated nanodiamonds exhibit the highest loading capacity while hydroxylated nanodiamonds are the most effective for sustained release. Therefore, a high degree of flexibility may be afforded by the use of nanodiamonds with different surface chemistries optimized for specific applications.
硫普罗宁是一种经美国食品药品监督管理局(FDA)批准的硫醇类药物,目前用于治疗胱氨酸尿症和类风湿性关节炎。然而,由于其抗氧化特性,它可能对多种其他病症有益。其更广泛应用的一个主要障碍是其生物利用度有限,这就需要给予高全身剂量以实现局部治疗效果。引入药物递送载体可以通过提供一种可控的、靶向释放的方式来解决这一困境。功能化纳米金刚石是一种很有前景的诊疗平台,已在包括药物递送在内的生物医学应用中展现出巨大潜力。设计纳米金刚石诊疗平台需要全面了解药物与平台之间的相互作用,而仅对有限数量的化合物进行了必要的物理化学研究。为了实现开发纳米金刚石 - 硫普罗宁治疗模式的长期目标,本研究旨在阐明纳米金刚石表面化学对硫普罗宁吸附和释放的影响。具体而言,测量了羧基化、羟基化和胺基化纳米金刚石的吸附等温线,并将其拟合到朗缪尔和弗伦德里希模型中,同时在pH值为4.0、5.8、7.3和8.1的溶液中监测释放情况。我们的结果表明,胺基化纳米金刚石表现出最高的负载能力,而羟基化纳米金刚石对持续释放最为有效。因此,通过使用针对特定应用优化的具有不同表面化学性质的纳米金刚石,可以提供高度的灵活性。